Cowan David A, Barker Campbell P
Department of Forensic Science & Drug Monitoring, King's College London, 150 Stamford Street, London, SE1 9NH, UK.
Bioanalysis. 2012 Jul;4(13):1545-8. doi: 10.4155/bio.12.160.
David A Cowan and Campbell P Barker speak to Ryan De Vooght-Johnson at Bioanalysis in May 2012 about the partnership between industry and academia for the setup and running of the doping-control laboratory for the London 2012 Olympic Games. David A Cowan is Director of the London 2012 anti-doping laboratory as well as Director of the King's College London Drug Control Centre, the UK's only WADA-accredited anti-doping laboratory, and Head of the Department of Forensic Science and Drug Monitoring. Cowan co-founded the Drug Control Centre in 1978 and became its Director in 1990. He has published extensively in the field of pharmaceutical analysis, especially as it relates to detecting drug administration in sport, and was awarded a personal chair in pharmaceutical toxicology in 1996. Cowan became Head of the Department of Forensic Science and Drug Monitoring at King's College London in 2002. He has served on a number of national and international committees, including the Council of Europe Working Party Investigating Drug Abuse in Sport that led to the first World Anti-Doping Convention, the Laboratory Representative on the International Olympic Committee's Medical Commission, and WADA's Laboratory Accreditation Subcommittee. He is a member of the Crippen Club for Distinguished Toxicologists. In 1998 he was awarded the IOC Trophy for Sport Ethics by the BOA. He was a founding member of the World Association of Anti-Doping Scientists and became its first President serving on its Executive Board between 2001 and 2004. He was a Visiting Laboratory Director at the Salt Lake City Winter Olympic Games 2002, where the first novel erythropoiesis-stimulating protein (NESP) positive was discovered. He was also a senior advisory scientist at both the Turin Winter Olympic Games in 2006 and the Beijing Olympic Games in 2008. He was also a member of the IOC Medical Commission for the Sydney Olympic Games in 2000 and the Vancouver Winter Olympic Games in 2010. The Drug Control Centre undertook the sample analysis during the 2002 Manchester Commonwealth Games and Cowan was Co-Director of the laboratory for the Commonwealth Games in Kuala Lumpur in 1998. Cowan, who has directed the laboratory at King's College London for many years, was a member of the bid team making the presentation to the International Olympic Committee in February 2005. Campbell P Barker has been leading GlaxoSmithKline's delivery of the London 2012 laboratory services since September 2009. Prior to that time he was Director of Global Strategic Projects in GlaxoSmithKline's Consumer Healthcare business from 2006, and from 1994 to 2006 he worked in R&D for Procter & Gamble. Barker holds a PhD in chemistry from the University of Durham.
2012年5月,大卫·A·考恩和坎贝尔·P·巴克在生物分析会议上与瑞安·德·沃格特 - 约翰逊谈到了行业与学术界为2012年伦敦奥运会兴奋剂检测实验室的设立和运营而建立的合作关系。大卫·A·考恩是2012年伦敦反兴奋剂实验室主任,也是伦敦国王学院药物控制中心主任,该中心是英国唯一一家获得世界反兴奋剂机构(WADA)认可的反兴奋剂实验室,同时他还是法医学与药物监测系主任。考恩于1978年共同创立了药物控制中心,并于1990年成为其主任。他在药物分析领域发表了大量著作,尤其在与检测体育运动中药物使用相关的领域,1996年被授予药物毒理学个人教授职位。2002年,考恩成为伦敦国王学院法医学与药物监测系主任。他曾在多个国家和国际委员会任职,包括导致首个《世界反兴奋剂公约》出台的欧洲委员会体育领域药物滥用调查工作组、国际奥委会医学委员会实验室代表以及WADA实验室认证小组委员会。他是杰出毒理学家克里平俱乐部的成员。1998年,他被英国奥林匹克协会授予国际奥委会体育道德奖。他是世界反兴奋剂科学家协会的创始成员,并在2001年至2004年期间担任其第一任主席,同时在执行委员会任职。他是2002年盐湖城冬奥会的客座实验室主任,在那里首次发现了新型促红细胞生成素(NESP)阳性案例。他还是2006年都灵冬奥会和2008年北京奥运会的高级顾问科学家。他也是2000年悉尼奥运会和2010年温哥华冬奥会国际奥委会医学委员会的成员。药物控制中心在2002年曼彻斯特英联邦运动会期间承担了样本分析工作,考恩是1998年吉隆坡英联邦运动会实验室的联合主任。多年来一直负责伦敦国王学院实验室的考恩,是2005年2月向国际奥委会做陈述的申办团队成员。坎贝尔·P·巴克自2009年9月以来一直领导葛兰素史克公司提供2012年伦敦奥运会实验室服务。在此之前,他从2006年起担任葛兰素史克公司消费者医疗保健业务全球战略项目主任,1994年至2006年在宝洁公司从事研发工作。巴克拥有杜伦大学化学博士学位。